Dynavax Technologies Net Worth

Dynavax Technologies Net Worth Breakdown

  DVAX
The net worth of Dynavax Technologies is the difference between its total assets and liabilities. Dynavax Technologies' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Dynavax Technologies' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Dynavax Technologies' net worth can be used as a measure of its financial health and stability which can help investors to decide if Dynavax Technologies is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Dynavax Technologies stock.

Dynavax Technologies Net Worth Analysis

Dynavax Technologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dynavax Technologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dynavax Technologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dynavax Technologies' net worth analysis. One common approach is to calculate Dynavax Technologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dynavax Technologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dynavax Technologies' net worth. This approach calculates the present value of Dynavax Technologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dynavax Technologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dynavax Technologies' net worth. This involves comparing Dynavax Technologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dynavax Technologies' net worth relative to its peers.
To determine if Dynavax Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dynavax Technologies' net worth research are outlined below:
Dynavax Technologies has a poor financial position based on the latest SEC disclosures
Over 99.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Citizens JMP Reiterates a Buy Rating on Dynavax Technologies With a Price Target of 31 - MSN

Dynavax Technologies Quarterly Good Will

2.03 Million

Dynavax Technologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dynavax Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dynavax Technologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
22nd of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Dynavax Technologies' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dynavax Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dynavax Technologies backward and forwards among themselves. Dynavax Technologies' institutional investor refers to the entity that pools money to purchase Dynavax Technologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
D. E. Shaw & Co Lp2025-03-31
2.5 M
Morgan Stanley - Brokerage Accounts2025-03-31
2.5 M
Blair William & Co2025-03-31
2.3 M
Amvescap Plc.2025-03-31
2.2 M
Northern Trust Corp2025-03-31
1.4 M
Two Sigma Investments Llc2025-03-31
1.3 M
Goldman Sachs Group Inc2025-03-31
1.3 M
Woodline Partners Lp2025-03-31
1.2 M
Charles Schwab Investment Management Inc2025-03-31
1.2 M
Blackrock Inc2025-03-31
20.3 M
Deep Track Capital, Lp2025-03-31
17.8 M
Note, although Dynavax Technologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Dynavax Technologies' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.29 B.

Market Cap

332.27 Million

Project Dynavax Technologies' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.03  0.03 
Return On Assets 0.03  0.03 
Return On Equity 0.05  0.05 
The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31.
When accessing Dynavax Technologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dynavax Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dynavax Technologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dynavax Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dynavax Technologies. Check Dynavax Technologies' Beneish M Score to see the likelihood of Dynavax Technologies' management manipulating its earnings.

Evaluate Dynavax Technologies' management efficiency

At this time, Dynavax Technologies' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.03 in 2025, whereas Return On Capital Employed is likely to drop (0) in 2025. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 22.2 M in 2025, whereas Other Assets are likely to drop slightly above 3 M in 2025. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for Next Year
Book Value Per Share 4.59  4.82 
Tangible Book Value Per Share 4.57  4.80 
Enterprise Value Over EBITDA 39.81  41.80 
Price Book Value Ratio 2.78  4.39 
Enterprise Value Multiple 39.81  41.80 
Price Fair Value 2.78  4.39 
Enterprise Value356.6 M317 M
Evaluating the management effectiveness of Dynavax Technologies allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dynavax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue
3.0954
Revenue
294.6 M
Quarterly Revenue Growth
0.342
Revenue Per Share
2.289
Return On Equity
(0.10)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dynavax Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dynavax Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dynavax Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Kelly MacDonald over a month ago
Disposition of 16000 shares by Kelly MacDonald of Dynavax Technologies subject to Rule 16b-3
 
David Novack over three months ago
Disposition of 10000 shares by David Novack of Dynavax Technologies at 14.0 subject to Rule 16b-3
 
David Novack over three months ago
Disposition of 14020 shares by David Novack of Dynavax Technologies at 13.58 subject to Rule 16b-3
 
David Novack over three months ago
Disposition of 32764 shares by David Novack of Dynavax Technologies at 14. subject to Rule 16b-3
 
David Novack over three months ago
Disposition of 22620 shares by David Novack of Dynavax Technologies subject to Rule 16b-3
 
Robert Janssen over three months ago
Disposition of 13000 shares by Robert Janssen of Dynavax Technologies subject to Rule 16b-3
 
Ryan Spencer over three months ago
Disposition of 11209 shares by Ryan Spencer of Dynavax Technologies at 13.2 subject to Rule 16b-3
 
Justin Burgess over three months ago
Disposition of 6666 shares by Justin Burgess of Dynavax Technologies subject to Rule 16b-3
 
Deep Track Biotechnology Master Fund, Ltd. over six months ago
Insider Trading
 
Justin Burgess over six months ago
Acquisition by Justin Burgess of 20000 shares of Dynavax Technologies at 11.7 subject to Rule 16b-3
 
David Novack over a year ago
Acquisition by David Novack of 20000 shares of Dynavax Technologies at 5.42 subject to Rule 16b-3
 
Cano Francis over a year ago
Disposition of 3615 shares by Cano Francis of Dynavax Technologies at 11.93 subject to Rule 16b-3

Dynavax Technologies Corporate Filings

17th of July 2025
Other Reports
ViewVerify
8K
17th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
13th of June 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
9th of June 2025
Other Reports
ViewVerify
Dynavax Technologies time-series forecasting models is one of many Dynavax Technologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dynavax Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Dynavax Technologies Earnings per Share Projection vs Actual

Dynavax Technologies Corporate Management

David NovackSr. VP of Operations and QualityProfile
Eric FringsSite VPProfile
Joe MetzingerVP OfficerProfile
Robert MDMedical DevelopmentProfile
Donn CasaleSenior OfficerProfile

Additional Tools for Dynavax Stock Analysis

When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.